CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue, net	$ 1,628	$ 684	$ 6,422	$ 684
Cost of revenue	1,193	453	3,341	453
Gross profit	435	231	3,081	231
Operating expenses:
Research and development	15,931	10,864	43,472	26,601
Sales and marketing	11,380	3,557	35,030	7,183
General and administrative	6,574	4,566	20,955	13,428
Total operating expenses	33,885	18,987	99,457	47,212
Loss from operations	(33,450)	(18,756)	(96,376)	(46,981)
Other income, net	710	564	2,189	1,392
Net loss	$ (32,740)	$ (18,192)	$ (94,187)	$ (45,589)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (1.06)	$ (0.63)	$ (3.04)	$ (1.68)
Weighted average common shares outstanding, basic and diluted (in shares)	30,982,192	28,834,808	30,938,026	27,180,244
Other comprehensive income:
Unrealized gain on marketable securities, net of tax of $0	$ 65	$ 63	$ 111	$ 7
Foreign currency translation adjustments	7	(10)	19	149
Total other comprehensive income	72	53	130	156
Comprehensive loss	(32,668)	(18,139)	(94,057)	(45,433)
ESKATA product sales
Revenue, net	510		2,043
Contract research
Revenue, net	$ 1,118	$ 684	3,379	$ 684
Other revenue
Revenue, net			$ 1,000